The NOPAIN Act (Non-Opioids Prevent Addiction in the Nation) is a federal law—enacted as Section 4135 of the Consolidated Appropriations Act, 2023, signed December 29, 2022—that requires Medicare to provide separate, additional payment for qualifying non-opioid pain treatments (drugs, biologicals, and devices) furnished in hospital outpatient departments (HOPDs) and ambulatory surgical centers (ASCs). The separate-payment window runs January 1, 2025 through December 31, 2027. For 2026, the key development is the CY2026 expansion: CMS increased the qualifying non-opioid product list from 11 to 18 products effective January 1, 2026, and added separately payable non-opioid pain-relief devices used in outpatient surgery. For wound care, the Act matters because many wound procedures—surgical debridement, biologic graft application, and procedural pain management—occur in exactly these outpatient settings, and the Act removes the financial barrier that previously incentivized opioid use over non-opioid alternatives. This guide explains how the law works, what changed for 2026, which treatments qualify, and how it intersects with wound-biologic workflows.
What the NOPAIN Act Does: A Plain-Language Summary
The NOPAIN Act is, at its core, a reimbursement reform. Before its passage, non-opioid pain devices and drugs used during outpatient surgery were typically bundled into the overall procedure payment. That bundling meant facilities absorbed the cost of more expensive non-opioid options and had a built-in financial reason to rely on cheaper opioids for postoperative pain. The Act flips that incentive: CMS must now pay separately—in addition to the standard surgical procedure payment—for qualifying non-opioid products that "replace, reduce, or avoid intraoperative or postoperative opioid use."
The separate-payment provision applies to items and services furnished on or after January 1, 2025, and before January 1, 2028. It is a temporary, three-year window designed to accelerate adoption of non-opioid pain management across outpatient surgery.
As CMS has implemented the law through annual rulemaking under the Hospital Outpatient Prospective Payment System (OPPS) and ASC payment system, the qualifying product list has expanded. The CY2026 rule—effective January 1, 2026—brought the roster of reimbursable non-opioid alternatives to 18 products (up from 11 in 2025) and expanded separately payable non-opioid pain-relief devices, which is the single most relevant change for wound-care and ambulatory surgery teams tracking this pathway in 2026.
What Changed for 2026: The CY2026 Expansion
- Effective date: January 1, 2026.
- Qualifying non-opioid products: 18 (up from 11 in CY2025).
- Device expansion: separately payable non-opioid pain-relief devices—including drug delivery systems and regional anesthesia pumps—added in ASC and HOPD settings.
- Window unchanged: services furnished on or after January 1, 2025 and before January 1, 2028.
The 2026 expansion matters for wound programs because the newly added devices are exactly the tools used in same-day surgical wound procedures: continuous local anesthetic delivery systems and regional anesthesia pumps that enable opioid-free or opioid-minimized recovery after debridement, grafting, and lower-extremity surgery. For foot and ankle surgery specifically—procedures that overlap heavily with wound-care populations—recent evidence reviews confirm that multimodal, non-opioid regimens built around regional blocks and long-acting local anesthetics achieve comparable or superior analgesia with substantially lower opioid exposure (Pascarella et al., 2025; Xu et al., 2023).
Key Defined Terms
- NOPAIN Act — Non-Opioids Prevent Addiction in the Nation Act; the common name for the separate-payment mandate codified at Section 4135 of the Consolidated Appropriations Act, 2023.
- Qualified non-opioid — A drug, biological, or device that replaces, reduces, or avoids intraoperative or postoperative opioid use and meets CMS criteria for separate payment under the Act.
- HOPD — Hospital Outpatient Department; a hospital-based setting where outpatient surgical and procedural services are furnished, billed under the OPPS.
- ASC — Ambulatory Surgical Center; a freestanding facility providing same-day surgical care, reimbursed under a separate ASC payment system.
- OPPS — Hospital Outpatient Prospective Payment System; the CMS payment system under which HOPD services, including NOPAIN Act non-opioid items, are reimbursed.
- Separate payment — Payment in addition to (not bundled into) the base procedure payment; the mechanism the Act mandates for qualifying non-opioid items.
- Multimodal analgesia — A perioperative pain strategy combining two or more non-opioid analgesic classes (e.g., regional anesthesia, local anesthetic infiltration, NSAIDs, acetaminophen) to minimize or eliminate opioid exposure.
Why the NOPAIN Act Matters for Wound Care
Wound care and the NOPAIN Act intersect in a specific way: many wound procedures that require pain management are performed in ASCs and HOPDs—the two settings the Act targets. Surgical debridement, skin grafting, flap closure, amniotic membrane application after sharp debridement, and the management of post-surgical wounds all generate procedural pain that clinicians must control. Historically, opioids were the default. The Act gives facilities a financial reason to choose non-opioid multimodal analgesia instead.
Evidence supports this shift. Non-opioid pain management strategies—including regional nerve blocks, local anesthetic infiltration systems, and structured multimodal pathways—have demonstrated meaningful reductions in postoperative opioid consumption across surgical populations, including orthopedic and lower-extremity procedures that overlap heavily with wound-care patients (Gessner et al., 2020; Pollak et al., 2021). For podiatric and foot-and-ankle surgery specifically—procedures that directly produce the chronic and surgical wounds wound centers manage—a 2025 comprehensive review of perioperative analgesia confirms that regional anesthesia and multimodal non-opioid regimens are central to modern opioid-sparing protocols (Pascarella et al., 2025), and dedicated reduction strategies built on education, risk identification, and multimodal analgesia have been formalized for foot and ankle surgery (Xu et al., 2023).
The broader policy environment reinforces the same direction. CMS continues to expand the ASC-covered procedures list, site-of-service payment differentials are narrowing, and the non-surgical paradigm in orthopedic and wound care is gaining reimbursement tailwinds. The NOPAIN Act is one structural piece of a larger shift away from opioid-dependent surgical pain control.
How Separate Payment Works in Practice
Under the Act, when a qualifying non-opioid drug, biological, or device is furnished in connection with a covered surgical procedure in an HOPD or ASC, Medicare pays for that item separately—on top of the payment for the procedure itself. This is distinct from the bundled model, where the cost of postoperative pain interventions was absorbed into a single package rate.
The practical effect for outpatient facilities and wound programs is straightforward: choosing a reimbursable non-opioid option no longer penalizes the facility financially. That change supports adoption of long-acting local anesthetics, non-opioid infusion pumps, and structured multimodal analgesia protocols in the same procedural encounters where biologic grafts and advanced wound therapies are applied.
Important boundary: wound biologics are not NOPAIN Act products
Amniotic membrane products—including AmnioAMP and Rampart—are reimbursed as wound-care biologics under their own HCPCS codes (for example, Q4347 covers dehydrated dual-layer amniotic membrane). They are not classified as NOPAIN Act "non-opioid pain" products. The two payment pathways operate independently: a facility may bill a non-opioid pain device under the NOPAIN Act separate-payment provision and an amniotic membrane graft under its wound-biologic code, in the same encounter, provided each meets its respective coverage and documentation requirements. Conflating the two is a common source of confusion that coding teams should clarify up front.
The clinical logic of the two tracks is complementary rather than competing: one controls procedural pain without opioids; the other supports the healing environment on the prepared wound bed. Amniotic membrane allografts carry synthesized randomized evidence in diabetic foot ulcers, the wound population where debridement-and-graft encounters are most common (Mohammed et al., 2022; Lakmal et al., 2021).
NOPAIN Act at a Glance: Reimbursement Summary (CY2026)
| Feature | Detail |
|---|---|
| Full name | Non-Opioids Prevent Addiction in the Nation Act |
| Legislative origin | Section 4135 of the Consolidated Appropriations Act, 2023 (signed December 29, 2022) |
| Core mechanism | Mandates separate, additional Medicare payment for qualifying non-opioid treatments in HOPDs and ASCs |
| Effective window | Services furnished on or after January 1, 2025, and before January 1, 2028 |
| CY2025 qualifying products | 11 non-opioid products on the separate-payment list |
| CY2026 qualifying products | 18 products effective January 1, 2026 (expansion via CY2026 OPPS/ASC rulemaking) |
| CY2026 device expansion | Separately payable non-opioid pain-relief devices (drug delivery systems, regional anesthesia pumps) added in ASC and HOPD settings |
| Settings covered | Hospital outpatient departments (OPPS) and ambulatory surgical centers |
| Relationship to wound biologics | Separate pathway; amniotic membrane products billed under own HCPCS codes (e.g., Q4347), not as NOPAIN Act items |
| Duration | Temporary (through 2027); extension requires congressional action |
Putting Non-Opioid Pain Strategies and Wound Biologics Together
The clinical logic is complementary, not competing. A patient undergoing surgical debridement followed by amniotic membrane graft application in an ASC benefits from two parallel care pathways: (1) a non-opioid multimodal analgesia protocol—supported by NOPAIN Act reimbursement—to control procedural and postoperative pain without opioids, and (2) a wound biologic to support the healing environment on the prepared wound bed. The first addresses pain; the second addresses the wound. Both are reimbursable in the same outpatient encounter under their respective mechanisms.
For wound programs evaluating this combined approach, the operational questions are: which non-opioid pain products on the CMS qualifying list fit our procedural mix, how do we document each separately for clean billing, and how does the non-opioid analgesia plan coordinate with our standard biologic application workflow? Facilities that answer these questions well position themselves to deliver opioid-sparing surgical wound care without leaving reimbursement on the table.
What This Means for Outpatient Wound Programs
- Audit your procedural pain pathways. Identify which ASC and HOPD wound procedures still default to opioids, and map which non-opioid alternatives on the 18-product CY2026 qualifying list could replace them.
- Separate the billing tracks. Ensure coding teams understand that NOPAIN Act non-opioid items and wound-biologic HCPCS codes (e.g., Q4347) are independent payment pathways that can coexist in one encounter.
- Build multimodal analgesia into debridement and graft protocols. Evidence-based non-opioid strategies reduce opioid exposure in the same procedures where biologics are applied (Gessner et al., 2020; Wickerts et al., 2011; Pascarella et al., 2025).
- Track the expiration clock. The separate-payment window ends December 31, 2027. Programs that build non-opioid workflows now are better positioned whether Congress extends the provision or not.
- Document the clinical rationale. Pairing non-opioid analgesia with biologic therapy reflects a coherent anti-inflammatory, healing-oriented philosophy that supports both payer documentation and clinical quality review.
Frequently Asked Questions
What is the NOPAIN Act?
The NOPAIN Act (Non-Opioids Prevent Addiction in the Nation) is federal law enacted as Section 4135 of the Consolidated Appropriations Act, 2023, signed December 29, 2022. It requires Medicare to provide separate, additional payment for qualifying non-opioid pain management drugs, biologicals, and devices in HOPDs and ASCs, for services furnished January 1, 2025 through December 31, 2027.
What changed for the NOPAIN Act in 2026?
Effective January 1, 2026, CMS expanded the qualifying non-opioid product list from 11 to 18 products and added separately payable non-opioid pain-relief devices (drug delivery systems and regional anesthesia pumps) in ASC and HOPD settings. The separate-payment window itself is unchanged: services furnished on or after January 1, 2025 and before January 1, 2028.
How does the NOPAIN Act affect wound care in 2026?
It matters in surgical and procedural wound care performed in ASCs and HOPDs. By paying separately for non-opioid pain interventions (regional blocks, local anesthetic systems, non-opioid infusions, acetaminophen/NSAID regimens), the Act removes the financial incentive to default to opioids for post-procedural pain. Wound biologics are reimbursed separately under their own codes and are not NOPAIN Act products.
When did separate payment for non-opioid treatments begin?
January 1, 2025. The provision covers qualifying non-opioid treatments furnished on or after that date and before January 1, 2028. It is a temporary three-year window.
Which treatments qualify for separate payment?
Non-opioid drugs, biologicals, and devices that replace, reduce, or avoid perioperative opioid use—long-acting local anesthetics, non-opioid analgesic infusion pumps, regional anesthesia agents, and certain non-opioid pharmaceuticals. CMS expanded the qualifying list to 18 products for CY2026 (up from 11 in 2025). Amniotic membrane wound biologics are reimbursed under separate HCPCS codes and are not on the NOPAIN Act list.
Does the NOPAIN Act cover amniotic membrane wound products?
No. Products like AmnioAMP and Rampart are wound-care biologics billed under dedicated HCPCS codes (e.g., Q4347). They are reimbursed through their own pathway, independent of the NOPAIN Act. Both pathways can apply in the same outpatient encounter.
Is the NOPAIN Act payment permanent?
No. It is temporary—covering services furnished before January 1, 2028. Congress would need to extend or codify it for the separate payment to continue beyond that date.
References
- Consolidated Appropriations Act, 2023, Section 4135 (Non-Opioids Prevent Addiction in the Nation Act). Signed into law December 29, 2022. U.S. Congress.
- CMS, Hospital Outpatient Prospective Payment System (OPPS) and Ambulatory Surgical Center Payment System rulemaking. Implementation of separate payment for qualifying non-opioid items and services, CY 2025–2027. Centers for Medicare & Medicaid Services.
- Pascarella G, et al. Perioperative Analgesia for Foot and Ankle Surgery: A Comprehensive Review. J Clin Med. 2025. PMID: 40944059.
- Xu AL, et al. Strategies for Reducing Perioperative Opioid Use in Foot and Ankle Surgery: Education, Risk Identification, and Multimodal Analgesia. Orthop Clin North Am. 2023. PMID: 37718087.
- Gessner DM, et al. Pain management in the orthopaedic trauma patient: Non-opioid solutions. Injury. 2020;51(7):1577-1583. PMID: 31079833.
- Pollak R, et al. Opioid-Free Recovery from Bunionectomy with HTX-011, a Dual-Acting Local Anesthetic Combining Bupivacaine and Meloxicam, as the Foundation of Non-Opioid Multimodal Analgesia. J Am Podiatr Med Assoc. 2021;111(3). PMID: 33471086.
- Wickerts L, et al. Coxibs: is there a benefit when compared to traditional non-selective NSAIDs in postoperative pain management? Minerva Anestesiologica. 2011;77(10):964-972. PMID: 21617597.
- Sjövall S, et al. Laparoscopic surgery: a narrative review of pharmacotherapy in pain management. Drugs. 2015;75(16):1855-1872. PMID: 26493289.
- Masaracchia MM, et al. Evolution of postoperative care: marked reduction of opioid consumption when ERAC pathway added to wound soaker therapy for cesarean delivery. J Matern Fetal Neonatal Med. 2023;36(1). PMID: 36191923.
- Mohammed YA, et al. Human amniotic membrane products for patients with diabetic foot ulcers. Do they help? A systematic review and meta-analysis. J Foot Ankle Res. 2022;15(1). PMID: 36104736.
- Lakmal K, et al. Systematic review on the rational use of amniotic membrane allografts in diabetic foot ulcer treatment. BMC Surg. 2021;21(1). PMID: 33588807.
Related Resources
- Medicare Coverage for Advanced Wound Biologics: An Eligibility Guide
- Reimbursement & Coding for Amniotic Membrane Allografts: 2026 Update
- Biologic Application Timing After Debridement: Evidence-Based Guidance
- Wound Care Biologics Comparison 2026
- Chronic Wound Biofilm Management: Pre-Graft Debridement Protocol
- Wound Center Biologics Evaluation Checklist
Build Opioid-Sparing, Biologic-Integrated Wound Protocols
NextGen Biologics supports wound-care teams with amniotic membrane products designed for practical use alongside non-opioid pain management in ASC and HOPD workflows.
Request samples of AmnioAMP or Rampart